
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
The latest update of AUA guidelines for management of organic erectile dysfunction will focus on novel treatment recommendations and suggestions for study designs that minimize conflicts of interest in post-marketing comparisons of oral drug therapies.





